Han Lim Pharmaceutical

Hanlim Pharm Co., Ltd. is a leading South Korean pharmaceutical company established in 1974, specializing in the development and manufacture of ethical drugs with a primary focus on ophthalmology and circulatory system health. The company is recognized for its robust R&D capabilities, having received multiple Korea New Drug Awards for innovative products like Lodien (S-amlodipine) for hypertension and Bronpass (HL301) for bronchitis. Hanlim's pipeline features advanced candidates such as HL217, a first-in-class eye drop for age-related macular degeneration, and HL235, a cathepsin K inhibitor for osteoporosis. With a global footprint in over 30 countries, the company operates state-of-the-art GMP-certified manufacturing facilities and continues to explore next-generation therapies, including natural medicines and stem cell-based treatments.